Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00038974 |
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
Condition | Intervention | Phase |
---|---|---|
Hepatitis C |
Drug: Pegylated interferon Drug: Ribavirin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94143 | |
United States, Florida | |
University of Miami School of Medicine | |
Miami, Florida, United States, 33136 | |
United States, Illinois | |
Rush University | |
Chicago, Illinois, United States, 60612 | |
United States, Maryland | |
University of Maryland School of Medicine | |
Baltimore, Maryland, United States, 21201 | |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
University of Michigan Medical Center | |
Ann Arbor, Michigan, United States, 48109 | |
United States, New York | |
New York-Presbyterian Medical Center | |
New York, New York, United States, 10032 | |
United States, North Carolina | |
University of North Carolina | |
Chapel Hill, North Carolina, United States, 27599 |
Study ID Numbers: | Virahep-C, U01 DK60329 |
Study First Received: | June 5, 2002 |
Last Updated: | October 11, 2005 |
ClinicalTrials.gov Identifier: | NCT00038974 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hepatitis C Interferon Ribavirin Efficacy |
Viral load Genetics Cytokines Immunology |
Antimetabolites Anti-Infective Agents Liver Diseases Hepatitis, Chronic Ribavirin Interferons Hepatitis, Viral, Human |
Antiviral Agents Hepatitis Virus Diseases Digestive System Diseases Hepatitis C Hepatitis C, Chronic |
Antimetabolites Anti-Infective Agents Liver Diseases RNA Virus Infections Molecular Mechanisms of Pharmacological Action Flaviviridae Infections Antineoplastic Agents Interferons Ribavirin |
Hepatitis, Viral, Human Antiviral Agents Pharmacologic Actions Hepatitis Virus Diseases Digestive System Diseases Therapeutic Uses Hepatitis C |